WASHINGTON—Life Sciences IP Review has named Covington Highly Commended for its Life Sciences IP Litigation Firm of the Year Award at the LSPN Awards 2026 ceremony in Boston. The Highly Commended distinction recognizes the highest-ranked finalist following the category winner and is determined by an independent panel of life sciences IP professionals from leading pharmaceutical companies and law firms.
The Life Sciences IP Litigation Firm of the Year Award recognizes a law firm that demonstrates excellence, innovation, and leadership in life sciences patent litigation. Covington was selected from a competitive field of 16 finalists representing many of the nation's leading intellectual property litigation practices.
Covington has one of the world's most active and respected life sciences litigation practices. More than 250 lawyers actively practice in the firm's life sciences group across multiple disciplines and geographies, integrating extensive regulatory, transactional, intellectual property, and litigation expertise. Covington is the only law firm recognized by Chambers & Partners as a top tier firm for Life Sciences across the U.S., UK, Europe, Asia‑Pacific, and Global guides, and has been named Life Sciences Practice Group of the Year by Law360 ten times. The firm's patent litigators represent leading pharmaceutical and biotechnology innovators in high‑stakes disputes, including Hatch‑Waxman and biologics litigation, FDA exclusivity challenges, PTAB proceedings, and complex multi‑jurisdictional matters, regularly appearing in federal district courts nationwide, before the U.S. International Trade Commission, and at the Federal Circuit.
Covington partner Christopher Sipes, Co‑Chair of the firm's Patent Litigation Group, was separately named Highly Commended for Patent Litigator of the Year at the same ceremony. The firm was also a finalist for the Case of the Year/Impact Case Award for its representation of Daiichi Sankyo in Seagen Inc. v. Daiichi Sankyo Co., Ltd., a matter led by Christopher, which resulted in the overturning of a multimillion‑dollar jury verdict.
Back
